Under the Paperwork Reduction Act of 1995, no perso TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Amaliantian Niverban		9/770,602		
		Filing Date	1635 JA		- REC	
		First Named Inventor				
		Art Unit			JAN ,	
		Examiner Name	Zara, J.		TEN	
Total Number of Pages in This Submission	17	Attorney Docket Number	HYB-003U	S1 (1006/004)	FECH CENTER	
	ENC	LOSURES (Check all that	annly)			
Fee Transmittal Form		Drawing(s)		After Allowand	e Communication	
Fee Attached		Licensing-related Papers		Appeal Comm	unication to Board d Interferences	
Amendment/Reply		Petition			unication to Group Brief, Reply Brief)	
After Final		Petition to Convert to a Provisional Application		Proprietary Inf		
	IĦ	Power of Attorney, Revocation		Status Letter		
Affidavits/declaration(s)	ᅢ	Change of Correspondence Addre	ess	Other Enclosu	re(s) (please	
Extension of Time Request	닏	Terminal Disclaimer		Identify below		
Express Abandonment Request		Request for Refund		•		
Information Disclosure Statement		CD, Number of CD(s)				
Certified Copy of Priority	Rema	arks				
Document(s)	1. Reti	urn postcard				
Response to Missing Parts/ Incomplete Application						
Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNA	TURE	OF APPLICANT, ATTORN	EY, OR AG	ENT		
Firm Keown & Associates or Wayne A. Keown, Ph.D.	, Reg. No	o. 33,923				
Individual Signature				<u> </u>		
Date ///						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**Commissioner for Patents, Washington, DC 20231.

Date

simpsion

Signature

Attorney Docket No. HYJ

EXAMINER: Zara, J.

ART UNIT: 1

IN APPLICATION OF:

Agrawal, S.

SERIAL NO.:

09/770,602

FILED:

July 26, 2001

Modulation of Oligonucleotide CpG-Mediated

Immune Stimulation by Posistional

Modification of Nucleosides

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Signature Melissa Simpsille

Printed Name: Melissa Simpson

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action dated October 7, 2003, please reconsider the above-referenced patent application in view of the following amendments.

Please amend the application as follows: